Physician profile
Stephen T Simpson
NPI 1013940998
$5,541.39
in general payments reported to CMS, 2019-2025
38 companies · $13.64 in 2025
The $13.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $712 · 2021: $1,223 · 2022: $1,188 · 2023: $970 · 2024: $202 · 2025: $13.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $924.53 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $688.92 | 2019-2024 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $656.76 | 2019-2022 | |
| Novo Nordisk INC | $481.39 | 2020-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $476.86 | 2021-2023 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $392.58 | 2021-2023 | |
| Glaxosmithkline, LLC. | $253.02 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $226.19 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $189.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.91 | 2019-2023 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $157.30 | 2020-2024 | Nexletol |
| Pfizer INC. | $149.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $114.63 | 2019-2023 | |
| Exact Sciences Corporation | $71.91 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.57 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.64 | 2019-2022 | |
| Allergan, INC. | $43.36 | 2020 | |
| Sunovion Pharmaceuticals INC. | $42.07 | 2019-2021 | |
| Zyla Life Sciences, INC. | $31.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.66 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $27.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.38 | 2020 | |
| Daiichi Sankyo INC. | $26.77 | 2020 | |
| Genentech USA, INC. | $25.03 | 2019 | |
| Sumitomo Pharma America, INC. | $23.70 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $21.55 | 2022 | |
| Melinta Therapeutics, LLC | $19.41 | 2022 | |
| Noven Therapeutics, LLC | $19.37 | 2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $18.18 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.79 | 2020 | |
| Grifols USA, LLC | $14.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2020 | |
| Eisai INC. | $14.28 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.86 | 2022 | |
| Mylan Specialty L.P. | $13.27 | 2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $13.18 | 2021 | |
| Horizon Therapeutics Plc | $13.08 | 2021 | |
| Medicure Pharma INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.